Get started
Author

Tara M. Young

Observed names: T M Young, Tara M Young, Tara Young
ORCID: 0000-0001-9677-3494
Observed ORCID: 0000-0001-9677-3494
OpenAlex ID: A5055898350
Autophagy protects tumors from T cell–mediated cytotoxicity via inhibition of TNFα-induced apoptosis
2020 · Tara M. Young, Claudia Reyes, et al. · Science Immunology · 113
The Growth Factor Granulin Interacts with Cyclin T1 and Modulates P-TEFb-Dependent Transcription
2003 · Mainul Hoque, Tara M. Young, et al. · Molecular and Cellular Biology · 73
FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling
2016 · C Daly, C Castanaro, et al. · Oncogene · 58
PDF
Human and Rodent Transcription Elongation Factor P-TEFb: Interactions with Human Immunodeficiency Virus Type 1 Tat and Carboxy-Terminal Domain Substrate
1999 · Y. Ramanathan, Syed M. Reza, et al. · Journal of Virology · 54
A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2021 · John O. DaSilva, Katie Yang, et al. · Molecular Cancer Therapeutics · 50
The Human I-mfa Domain-Containing Protein, HIC, Interacts with Cyclin T1 and Modulates P-TEFb-Dependent Transcription
2003 · Tara M. Young, Qi Wang, et al. · Molecular and Cellular Biology · 47
Disruption of nuclear envelope integrity as a possible initiating event in tauopathies
2022 · Marine Prissette, Wen Fury, et al. · Cell Reports · 41
PDF
A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
2023 · Andres E. Perez Bay, Devon Faulkner, et al. · Molecular Cancer Therapeutics · 25
Genome-scale CRISPR activation screen uncovers tumor-intrinsic modulators of CD3 bispecific antibody efficacy
2019 · Corinne E. Decker, Tara Young, et al. · Scientific Reports · 23
PDF
Developmental Regulators Containing the I-mfa Domain Interact with T cyclins and Tat and Modulate Transcription
2007 · Qi Wang, Tara M. Young, et al. · Journal of Molecular Biology · 18
Cellular mRNA Activates Transcription Elongation by Displacing 7SK RNA
2007 · Tara M. Young, Michael Tsai, et al. · PLoS ONE · 17
PDF
The 3′UTR of HIC mRNA improves the production of recombinant proteins in Chinese hamster ovary cells
2008 · Jaron Liu, Sebastian C.Y. Ku, et al. · Journal of Biotechnology · 2
Fig S1 from A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
2025 · Andres E. Perez Bay, Devon Faulkner, et al.
PDF
Fig S3 from A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
2025 · Andres E. Perez Bay, Devon Faulkner, et al.
PDF
Fig S6 from A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
2025 · Andres E. Perez Bay, Devon Faulkner, et al.
PDF
Supplementary Table 1 from A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
2025 · Andres E. Perez Bay, Devon Faulkner, et al.
Fig S4 from A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
2025 · Andres E. Perez Bay, Devon Faulkner, et al.
PDF
Fig S5 from A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
2025 · Andres E. Perez Bay, Devon Faulkner, et al.
PDF
Fig S2 from A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
2025 · Andres E. Perez Bay, Devon Faulkner, et al.
PDF
Table S1 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025 · John O. DaSilva, Katie Yang, et al.
Table S4 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025 · John O. DaSilva, Katie Yang, et al.
Figure S3 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025 · John O. DaSilva, Katie Yang, et al.
Data from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025 · John O. DaSilva, Katie Yang, et al.
Table S3 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025 · John O. DaSilva, Katie Yang, et al.
Table S2 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025 · John O. DaSilva, Katie Yang, et al.
Works count: 44
Citation count: 521
H-index: 11
I10-index: 11
Year
Topic
Type